Sharath Kumar
Ledipasvir sold below the brand Harvoni among others, may be a medication accustomed treat viral hepatitis. It's a fixeddose combination of ledipasvir and sofosbuvir. Cure rates are ninety four to ninety nine in individuals infected with viral hepatitis virus (HCV) genotype one. Some proof additionally supports use in HCV genotype three and four. It’s taken daily orally for 8–24 weeks. It is usually well tolerated. Common aspect effects embrace muscle pains, headache, nausea, rash, and cough. It is unclear if use in physiological state is safe for the baby. Ledipasvir works by decreasing the activity of NS5A and sofosbuvir works by decreasing the activity of NS5B enzyme.
English 
Spanish 
Chinese 
German 
French 
Japanese 
Portuguese 
Hindi